Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases

Posted on October 4, 2024 by MissionIR
  • Annovis Bio recently filed three new patents covering combinations of buntanetap, its lead compound, with a GLP-1 agonist (such as dulaglutide/Trulicity) and with PDE5 inhibitors (such as sildenafil/Viagra), as well as a combination of all three
  • The company believes these combinations create a broader approach to treating neurodegenerative diseases
  • Preclinical studies have demonstrated these combinations significantly improve cognition in Alzheimer’s mouse models
  • Combinations of buntanetap with PDE5 inhibitors and GLP-1 agonists are now ready to enter phase 3 clinical studies (buntanetap is in phase 3, and a number of PDE5 inhibitors and GLP-1 agonists are already on the market)

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently filed three new patents (https://ibn.fm/wWksA). The patent applications seek protection for innovative combination therapies involving buntanetap that improve cognition beyond normal levels.

Specifically, the patent filings cover buntanetap combined with a glucagon-like peptide-1 (“GLP-1”) agonist, buntanetap combined with a phosphodiesterase 5 (“PDE5”) inhibitor, and a combination of all three. According to the company, these combinations create a multi-sided approach to treating neurodegenerative diseases.

The motivation to seek patent protection stems from the successes of recent preclinical studies, which have provided compelling results that demonstrate the strong potential for the combinations to enhance cognition. Data from these studies have shown that buntanetap combined with PDE5 inhibitors or GLP-1 agonists improves cognitive function in Alzheimer’s mouse models beyond levels observed in healthy controls.

Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis, noted, “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement.” Maria went on to state that the combination of buntanetap with Trulicity and Viagra has the potential to “restore cognition to healthy levels” and improve it “beyond normal level, offering new hope in the fight against dementia.”

According to an August 6 news release, buntanetap significantly amplifies the effects of Trulicity on memory and learning, leading to a “6- to 10-fold increase in efficacy,” according to Maria. The company observes that this synergy helps enhance treatment outcomes while simultaneously lessening potential side effects (https://ibn.fm/0zRY1).

Buntanetap targets neurodegeneration by inhibiting the production of various neurotoxic proteins, including TDP43, alpha-synuclein, tau, and amyloid beta. It improves the affected function in neurodegenerative diseases, enhances cognition in early AD patients, improves motor function and stops cognitive decline in PD patients.

The company’s recent Phase 2/3 study of buntanetap in patients with early (mild to moderate) AD showed a statistically significant improvement in cognition. The Phase 2/3 study gave the company valuable information for a planned Phase 3 pivotal trial (https://ibn.fm/sVv02). In addition, the company has separately completed a Phase 3 study of buntanetap in patients with early PD (https://ibn.fm/FIM3D).

“Since buntanetap has completed Phase 3 studies as a standalone treatment, and a number of GLP-1 agonists and PDE5 inhibitors are FDA-approved, these combinations are well positioned for Phase 3 human trials,” expressed Maria in the Sept. 30 news release announcing the patent filings.

The new patent applications are expected to further strengthen the company’s expansive intellectual property portfolio. Annovis currently has more than 35 total issued patents, plus plenty more pending applications in various jurisdictions, according to its latest Form 10-K filing (https://ibn.fm/YzxJB).

The issued patents and pending applications speak to the company’s resolve to “protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties,” as a source of its unique value to shareholders and competitive advantage.

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

Posted in Annovis Bio Inc. ANVS | Leave a comment

SuperCom Ltd. (NASDAQ: SPCB) Secures 5th Government EM Contract for Domestic Violence Offender Monitoring

Posted on October 3, 2024 by MissionIR
  • Electronic monitoring (“EM”) technology is becoming a popular go-to means of tracking the movements of crime suspects, including domestic violence (“DV”) offenders, while they remain unjailed and free to continue productive activity in society
  • SuperCom Ltd., a secure solutions provider for the e-Government, IoT and Cybersecurity sectors, is competitively marketing its PureSecurity EM platform to government clients who need SuperCom’s resources for parole and probation supervision
  • SuperCom recently announced it has secured its fifth national contract in Europe to provide supervised monitoring of domestic violence suspects and an effective alert system for DV victims
  • Analysts forecast Europe’s average daily caseload of individuals monitored with EM will increase from 64,000 people to 94,000 between 2023 and 2028

Electronic monitoring (“EM”) technology is increasingly being deployed as a public safety solution that has the potential to ease the concerns of governments and citizens alike around the world. Using a variety of modern technologies, law enforcement and other safety institutions are able to track the movements of individuals identified as criminal suspects while those suspects remain free from incarceration and interact with society.

Riding the wave of the EM technology market’s growth, SuperCom (NASDAQ: SPCB) and its PureSecurity suite of EM solutions have built a strong reputation for providing products and services that help criminal justice systems monitor the movements of offenders and suspects. 

SuperCom announced recently (Sept. 23) that it has secured a new three-year national contract with government officials in Europe to monitor domestic violence (“DV”) suspects, providing vulnerable victims and authorities with a level of assurance that they’ll be notified if the offender is anywhere in their vicinity, allowing authorities to react promptly and enabling victims to take measures to enhance their safety.

The contract marks the company’s fifth compact with a national government office in Europe to provide domestic violence subject monitoring capabilities in the European Union (“EU”) region. This marks SuperCom’s continued expansion in Europe, where it has already deployed a substantial number of units, outpacing its competitors and solidifying its position as a leader in domestic violence monitoring solutions.

“Winning our fifth national domestic violence contract in Europe is a testament to the trust governments place in our technology and our commitment to enhancing public safety,” SuperCom President and CEO Ordan Trabelsi stated in the company’s announcement (https://ibn.fm/5tSea). “Our DV monitoring solution offers real-time tracking, communication and security, providing authorities with a powerful tool to improve the protection of vulnerable individuals and promote offender accountability.”

SuperCom continues to establish its competitiveness in a small, niche market as it gains successive monitoring technology contracts in Europe and the United States.

Research and Markets analysts’ report on the electronic monitoring market last year noted that Europe was undertaking an average daily caseload of 64,000 individuals being monitored through EM technology, while the analysts found 518,000 being monitored in North America on a daily average basis. The analysts forecast that those numbers will grow to 680,000 in North America, and the United States was managing an average daily caseload of 518,000 individuals being monitored through EM technology, while the analysts found 64,000 being monitored in Europe on a daily average basis.

The analysts forecast that those numbers will grow to 680,000 in North America and 94,000 in Europe by 2028. They also expect the market to grow with a five-year CAGR of 7.2 percent to a value of $2.3 billion by 2028 when Europe and North America’s sectors are combined with the EM sector in Latin America (https://ibn.fm/uXLce).

Domestic violence intervention is a significant client use case for EM technology. The PureSecurity platform transmits information on a monitored subject’s whereabouts in real time, not simply on a flat geographical footprint but with elevation data as well to deliver a more 3-D perspective for apartment dwellers and office workers. The system then notifies victims via cell phone if an alert to an offender’s location is needed.

“The new contract represents a significant step in enhancing domestic violence prevention and intervention capabilities in this EU region,” SuperCom’s announcement states.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

Posted in SuperCom Ltd. SPCB | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Reports 6791% QoQ Revenue Growth, Continued Decrease in Monthly Cash Burn

Posted on October 2, 2024 by MissionIR

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced expectations to report a significant revenue increase for the quarter ended September 30, 2024. The company anticipates recording approximately $4.5 million in revenue in the just-ended quarter, compared to $65,235.00 in the previous quarter ended June 30, 2024, a quarter-over-quarter increase of 6791%.

According to the announcement, the company’s monthly cash burn for the quarter ended September 30, 2024, is approximately $12.7 million per month, down from $12.8 million for the quarter ended June 30, 2024, and $18.1 million for the quarter ended March 31, 2024. The announcement stated that Mullen expects to continue to reduce its monthly cash burn “with operating reductions throughout 2025 with the expectation to achieve breakeven on a cash basis by December 2025.”

“Our revenue is up significantly, and our cash burn continues to decrease,” said David Michery, CEO and Chairman of Mullen. “We are going into the remainder of 2024 with strong momentum, and I am focused on closing out the calendar year on an extremely positive trajectory.”

To view the full press release, visit https://ibn.fm/OEqfx

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Mullen Automotive Inc. MULN | Leave a comment

SOBRsafe Inc. (NASDAQ: SOBR) Announces Moves Undertaken to Ensure Sustained Financial Success Based Upon Recent Positive Results

Posted on October 2, 2024 by MissionIR
  • SOBRsafe CEO and Chairman Dave Gandini recently provided a video update discussing the company’s plans to achieve sustained financial success and build a global legacy
  • The company intends to regain compliance with Nasdaq’s listing requirements by effecting a reverse stock split and issuing a new capital raise to exceed the minimum stockholders’ equity threshold
  • Retaining its Nasdaq listing is seen as critical to attract and raise capital to continue building operations
  • The company has added 35 new accounts in the first and second quarter of the 2024 fiscal year
  • SOBRsafe is also implementing robust sales and marketing strategies to present its suite of products to more potential customers in the behavioral health sector

SOBRsafe (NASDAQ: SOBR), a company leveraging its advanced next-generation transdermal alcohol detection technology to empower recovery, recently shared a video update from CEO and Chairman Dave Gandini. In the update, Gandini discussed the company’s approved compliance strategies to ensure continued listing on the Nasdaq Capital Markets (https://ibn.fm/Uy9XX).

“Continuing Nasdaq compliance and maintaining our listing is a top priority above all else. Why? First, we are committed to providing our investors with a clear path to growth, value and liquidity, which requires that Nasdaq listing. With our continued listing and growth, we will attract affordable capital,” said Gandini.

According to Gandini, the company has until October 23 to comply with the minimum bid price requirement. And in line with this requirement, the company plans to pursue a reverse stock split, following approval by an overwhelming majority (87%) of its shareholders. The company also has until October 23 to “demonstrate long-term compliance with the required minimum of $2.5 million in shareholder equity.” According to Gandini, the company hopes to address this requirement through a yet-to-be-announced capital raise.

Gandini also talked about the company’s sales and marketing strategies, noting that SOBRsafe has been focusing its sales efforts primarily on the behavioral health market since late last year. By focusing on this market, Gandini explained, the company aims to “reduce costs, streamline operations, improve outcomes, and save lives.”

The company develops and sells a passive, preventative alcohol screening device called the SOBRcheck(TM) and a continuous alcohol monitoring wristband called SOBRsure(TM). SOBRcheck is fitted with two sensors, one of which scans biometrics data from a user’s fingerprint, with the other detecting any alcohol excreted from the pores in the tip of the finger. The device is powered by the SOBRsafe software platform, which relays results in real time, improving employee throughput at point-of-care facilities. The SOBRsure(TM) device is equally configured to provide app-based reporting via the SOBRsafe platform, supports GPS tracking, and sends removal alerts.

“In 2024, and consistent with our strategy, we have now established our technology, with our first revenue-generating customers in behavioral health growing to 35 accounts in the first and second quarters of this year. In addition, we entered the equivalent verticals in Australia and New Zealand and are gaining traction through a channel partner that we are very excited about. Finally, further international expansion is underway,” Gandini continued.

The company is also keen on marketing its behavioral health solutions to even more facilities and potential customers and has launched a national B2B marketing campaign. “Now that we’ve achieved the behavioral health validation I described earlier, we are at a version of that same commercial evolution. We are working with national communication leaders to rapidly build the SOBRsafe brand,” he remarked.

Gandini noted that the campaign, which draws national agencies across public relations and digital and social media marketing, is designed to capture over four million projected views in the next year and present the company’s suite of hardware and software products to more than 45,000 behavioral health decision makers in the U.S. (https://ibn.fm/N4Fie). “We believe that our approach will increase demand, drive sales and gain market share for us in the fourth quarter and into 2025,” conveyed Gandini.

SOBRsafe believes that its strategy, as discussed in the update, will enable it to achieve sustained financial success, increase shareholder value over the long term, and build a global legacy. And this depends on a cascade of related factors. “First to significantly grow sales, we must invest in national marketing, and we are well on our way. Second, to empower this investment, we must acquire additional capital. Third, to attract this capital, we must retain our Nasdaq listing. And finally, to retain our Nasdaq listing, we are required to split the stock,” Gandini concluded.

To view the video update, visit https://ibn.fm/3RsiG.

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

Posted in SOBRsafe Inc. SOBR | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

Posted on October 2, 2024 by MissionIR

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary, Clene Nanomedicine Inc., has closed on a registered direct offering and concurrent private placements. According to the announcement, the transactions consist of common stock and warrants and were with a healthcare-focused institutional investor and existing shareholders, including insiders. Gross proceeds of the offerings and placements totaled an estimated $7.3 million with the potential for additional capital through the future exercise of warrants. Clene also announced the amendment of its existing debt facility with Avenue Venture Opportunities Fund, L.P.

“We are appreciative for the support of both our new healthcare-focused institutional investor as well as existing shareholders, including insiders,” said Clene board chair David Matlin in the press release. “The capital raised in this offering along with the debt principal deferral from Avenue will allow the company to fund itself while in discussions with the FDA to potentially file an NDA under the accelerated approval pathway by year end. Most importantly, this financing also enables people with ALS who currently take CMN-Au8 under our compassionate use programs to continue receiving drug while Clene discusses its data with the FDA.”

To view the full press release, visit https://ibn.fm/xeyKW

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Ideally Positioned as Hybrid-Fueled Surge in PGM Demand Creates Key Opportunity

Posted on October 2, 2024 by MissionIR
  • Reuters reports that “a surge in sales of hybrid cars as electric vehicle take-up slows is set to provide an unexpected boost to demand for platinum group metals.”
  • While the global supply of platinum and palladium has been relatively stable, the increase in demand from the automotive sector is expected to create supply pressures.
  • Platinum Group Metals Ltd., a prominent player in the PGM space, is well positioned to capitalize on this trend.

The automotive industry’s shift toward hybrid and electric vehicles (“EVs”) is reshaping numerous sectors, including the precious metals market. A recent Reuters article highlights how this transition is driving the demand for platinum group metals (“PGMs”), a trend that is poised to benefit key industry players such as Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM).

“A surge in sales of hybrid cars as electric vehicle take-up slows is set to provide an unexpected boost to demand for platinum group metals (“PGMs”) in the coming years, similar to the extended lifespan now predicted for coal,” reported Reuters, in an article titled “Hybrid Cars Throw Lifeline to Platinum Metals.”

The article noted that PGMs had been facing a decline in demand because their main use has been to clean auto exhaust, a process that is not needed in pure EVs. However, “a tapering in growth of EV sales, and a surge in demand for hybrid cars that need catalytic converters to curb pollution, have given PGMs a new lease on life that could put a floor under prices and keep some mines open longer,” the article continued.

According to Reuters, the rise in hybrid car production is providing a significant boost to the platinum market. PGMs, including platinum, palladium and rhodium, are essential for the catalytic converters used in these vehicles. These metals facilitate the chemical reactions that convert harmful exhaust gases into less-dangerous emissions. With hybrid vehicles becoming more prevalent, the demand for these metals is growing.

Platinum, in particular, is gaining renewed importance in the automotive industry. As hybrid vehicles become more advanced, the need for high-performance catalytic converters is increasing. Platinum’s unique properties — its catalytic efficiency and resistance to high temperatures — make it a preferred choice for these applications.

The Reuters article notes that while the global supply of platinum has been relatively stable, the increase in demand from the automotive sector is expected to create supply pressures. This imbalance between supply and demand is driving up platinum prices, which in turn impacts the broader market for PGMs.

Platinum Group Metals Ltd., an up-and-coming player in the PGM space, is well positioned to capitalize on this trend. The company is engaged in the development of the Waterberg Project in South Africa. This project is strategically aligned with the growing demand for platinum and other PGMs, as it aims to produce large quantities of these crucial metals.

The shift toward hybrid vehicles is not only transforming the automotive industry but also creating significant opportunities in the precious metals market. By expanding its production capabilities and capitalizing on the growing market, Platinum Group Metals Ltd. is looking to benefit from the increase in PGM demand, potentially driving substantial growth and success in the evolving landscape of sustainable transportation.

For more information, visit the company’s website at www.PlatinumGroupMetals.net.

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

Posted in Platinum Group Metals Ltd. PLG | Leave a comment

MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS), Japan Tobacco Inc. Announce Planned Partnership to Leverage Quantum Computing, AI in Drug Discovery

Posted on October 2, 2024 by MissionIR

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) announced plans to partner on a joint proof-of-concept project to explore the use of quantum computing technology and artificial intelligence (“AI”) to accelerate the speed and quality of the drug discovery process, i.e., “Quantum AI-driven Drug Discovery.” The project aims to pioneer a new process for discovering ‘first-in-class’ pharmaceutical small compounds. Upon completion of the proof-of-concept project, JT’s pharmaceutical division intends to further advance the developed Quantum AI-driven Drug Discovery analysis systems and eventually apply the quantum computing technology in production operations.

“Pharmaceutical companies need to maintain competitiveness while addressing the challenges of difficulty, uncertainty, and duration in new drug development, creating an environment that is accelerating the speed and quality for AI drug discovery,” said Dr. Alan Baratz, CEO of D-Wave. “D-Wave is committed to supporting JT’s pharmaceutical division in maximizing the capabilities of AI through quantum computing technology, with the goal of expanding the exploration space for pharmaceutical small compounds.”

To view the full press release, visit https://ibn.fm/pW8a0

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M

Posted on September 30, 2024 by MissionIR

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused institutional investor. The company also noted it had entered into additional agreement and placements with current investors as well as directors and officers of Clene. Gross proceeds from the transactions will total an estimated $7.3 million, before standard deductions and fees. Canaccord Genuity is acting as sole placement agent for the offerings, which are expected to close on or about Oct. 1, 2024.

To view the full press release, visit https://ibn.fm/GdcBb

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS), Staque Join Forces to Advance Annealing Quantum Computing Adoption in the Middle East

Posted on September 30, 2024 by MissionIR
  • The strategic partnership between D-Wave and Staque aims to accelerate the commercial adoption of annealing quantum computing solutions in the region.
  • The two companies will leverage D-Wave’s quantum computers and hybrid solvers to help customers develop and deploy quantum and hybrid quantum applications to address enterprise optimization and AI problems.
  • The partnership was revealed at the first-ever Qubits UAE event in Dubai, which was organized jointly by D-Wave, Staque, and Staque’s regional partner, SquareOne.

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, announced a new strategic partnership with Staque, a leading consulting and development practice focused on AI, blockchain and quantum computing, designed to step up the commercial adoption of annealing quantum computing across the Middle East (https://ibn.fm/TNAND).

The partnership was unveiled at the first-ever Qubits UAE event, which D-Wave organized in collaboration with Staque and Staque’s partner in the region, SquareOne, a leading provider of business transformation technologies in the Middle East and Africa. Held in Dubai on September 20, 2024, Qubits UAE featured specially curated content from D-Wave’s annual Qubits user conference, which took place in Boston on June 17-18 this year. The event showcased “success powered by quantum” through business optimization use cases, progress in quantum-fueled AI technology, and demonstrations of annealing quantum computing performance over classical computing.

D-Wave and Staque plan to work together to help customers develop and deploy quantum and hybrid quantum applications designed to address enterprise optimization and AI problems. This will be achieved by leveraging D-Wave’s quantum computers and hybrid solvers, accessible through D-Wave’s Leap(TM) quantum cloud service. The companies will be able to explore quantum applications that address complex challenges facing today’s organizations including supply chain management, utility grid optimization, portfolio optimization and port optimization. The strategic partnership comes as countries in the Middle East are increasingly focused on diversifying their economies, expanding into areas such as logistics, financial services and advanced technology, according to the International Monetary Fund.

“By partnering with D-Wave, the world’s first commercial quantum computing company, we’re able to bring incredible computational processing power to bear for our clients, with the intention of helping them take advantage of advanced technology solutions that can drive their businesses forward,” said Dr. Muhammad Khan, CEO and founder of Staque.

“We believe organizations must embrace today’s advanced technologies such as quantum computing and AI in order to succeed in today’s highly competitive and complex environment,” said Lorenzo Martinelli, chief revenue officer at D-Wave. “Staque recognizes the transformative impact that annealing quantum computing could have on its customers, and our shared commitment to redefining what’s possible with technology makes this partnership very exciting.”

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Posted on September 27, 2024 by MissionIR

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands.

Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as soon as the first dosing has started, potentially in late October. The company anticipates the final doses will be administered in late November.

To view the full press release, visit https://ibn.fm/st4oD

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment